Cytosorbents Corp Company Profile (NASDAQ:CTSO)

About Cytosorbents Corp (NASDAQ:CTSO)

Cytosorbents Corp logoCytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company's purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. The Company's CytoSorb is an extracorporeal cytokine filter and is designed to reduce the cytokine storm that causes inflammation, organ failure and death in common critical illnesses, such as sepsis, burn injury, trauma, lung injury and pancreatitis. In addition, CytoSorb is used in other inflammatory conditions, such as cardiac surgery and autoimmune disease flares and cancer cachexia. It also has other products under development based upon its blood purification technology, including HemoDefend, ContrastSorb, DrugSorb, BetaSorb and others.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Laboratories & Research
  • Sub-Industry: N/A
  • Symbol: NASDAQ:CTSO
  • CUSIP: N/A
  • Web:
  • Market Cap: $122.27 million
  • Outstanding Shares: 28,108,000
Average Prices:
  • 50 Day Moving Avg: $4.61
  • 200 Day Moving Avg: $5.24
  • 52 Week Range: $3.95 - $6.90
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -18.13
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $10.83 million
  • Price / Sales: 11.29
  • Book Value: ($0.06) per share
  • Price / Book: -72.50
  • EBIDTA: ($10,770,000.00)
  • Net Margins: -120.04%
  • Return on Equity: -193.13%
  • Return on Assets: -85.97%
  • Debt-to-Equity Ratio: 3.26%
  • Current Ratio: 1.81%
  • Quick Ratio: 1.60%
  • Average Volume: 166,398 shs.
  • Beta: -0.07
  • Short Ratio: 14.55

Frequently Asked Questions for Cytosorbents Corp (NASDAQ:CTSO)

What is Cytosorbents Corp's stock symbol?

Cytosorbents Corp trades on the NASDAQ under the ticker symbol "CTSO."

How were Cytosorbents Corp's earnings last quarter?

Cytosorbents Corp (NASDAQ:CTSO) posted its earnings results on Monday, May, 8th. The company reported ($0.05) EPS for the quarter, topping analysts' consensus estimates of ($0.11) by $0.06. The company had revenue of $3.11 million for the quarter, compared to the consensus estimate of $2.99 million. Cytosorbents Corp had a negative return on equity of 193.13% and a negative net margin of 120.04%. View Cytosorbents Corp's Earnings History.

Where is Cytosorbents Corp's stock going? Where will Cytosorbents Corp's stock price be in 2017?

5 brokers have issued 1 year target prices for Cytosorbents Corp's shares. Their predictions range from $9.00 to $24.00. On average, they expect Cytosorbents Corp's stock price to reach $13.45 in the next year. View Analyst Ratings for Cytosorbents Corp.

What are analysts saying about Cytosorbents Corp stock?

Here are some recent quotes from research analysts about Cytosorbents Corp stock:

  • 1. Maxim Group analysts commented, "CytoSorbents issued a letter to its shareholders today highlighting the progress the company achieved in 2016." (4/19/2017)
  • 2. HC Wainwright analysts commented, "CytoSorbents reported full-year 2016 financial results and held a conference call on March 3. The company reported revenues of $9.5M, higher than our estimate of $8.7M, and a net loss of $0.47 per share, compared to our estimated net loss of $0.40 per share. The differences mainly resulted from higher-than-expected product sales, offset by increased R&D and SG&A increases. We have updated our model to reflect the 2016 financial results." (3/6/2017)

Are investors shorting Cytosorbents Corp?

Cytosorbents Corp saw a drop in short interest in the month of March. As of March 31st, there was short interest totalling 759,170 shares, a drop of 2.5% from the March 15th total of 778,803 shares. Based on an average daily volume of 251,285 shares, the short-interest ratio is presently 3.0 days.

Who are some of Cytosorbents Corp's key competitors?

Who owns Cytosorbents Corp stock?

Cytosorbents Corp's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (2.22%), Skylands Capital LLC (1.24%), Sabby Management LLC (0.86%), Geode Capital Management LLC (0.50%), Cowen Group Inc. (0.22%) and California Public Employees Retirement System (0.18%). Company insiders that own Cytosorbents Corp stock include Al Kraus, Kathleen P Bloch, Michael G Bator, Phillip P Chan and Vincent Capponi. View Institutional Ownership Trends for Cytosorbents Corp.

Who bought Cytosorbents Corp stock? Who is buying Cytosorbents Corp stock?

Cytosorbents Corp's stock was acquired by a variety of institutional investors in the last quarter, including Skylands Capital LLC, Sabby Management LLC, Cowen Group Inc., Segantii Capital Management Ltd, Vanguard Group Inc. and Geode Capital Management LLC. Company insiders that have bought Cytosorbents Corp stock in the last two years include Kathleen P Bloch, Michael G Bator and Phillip P Chan. View Insider Buying and Selling for Cytosorbents Corp.

How do I buy Cytosorbents Corp stock?

Shares of Cytosorbents Corp can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Cytosorbents Corp stock cost?

One share of Cytosorbents Corp stock can currently be purchased for approximately $4.35.

Analyst Ratings

Consensus Ratings for Cytosorbents Corp (NASDAQ:CTSO) (?)
Ratings Breakdown: 5 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $13.45 (209.20% upside)

Analysts' Ratings History for Cytosorbents Corp (NASDAQ:CTSO)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/22/2017Maxim GroupSet Price TargetBuy$10.00MediumView Rating Details
5/15/2017B. RileyReiterated RatingBuy$11.25LowView Rating Details
5/9/2017AegisReiterated RatingBuy$9.00HighView Rating Details
3/6/2017HC WainwrightBoost Price TargetBuy$11.50 -> $13.00N/AView Rating Details
10/4/2016Brean CapitalInitiated CoverageBuy$24.00N/AView Rating Details
10/29/2015WBB SecuritiesUpgradeSpeculative Buy -> Buy$13.00N/AView Rating Details
(Data available from 5/25/2015 forward)


Earnings History for Cytosorbents Corp (NASDAQ:CTSO)
Earnings by Quarter for Cytosorbents Corp (NASDAQ:CTSO)
Earnings History by Quarter for Cytosorbents Corp (NASDAQ:CTSO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2017Q1 2017($0.11)($0.05)$2.99 million$3.11 millionViewListenView Earnings Details
3/3/2017Q4 2016($0.10)($0.16)$2.59 million$3.08 millionViewN/AView Earnings Details
11/7/2016Q3($0.11)($0.11)$2.35 million$2.14 millionViewListenView Earnings Details
8/9/2016Q216($0.09)($0.12)$2.18 million$1.90 millionViewN/AView Earnings Details
5/9/2016Q116($0.10)($0.08)$1.73 million$1.80 millionViewN/AView Earnings Details
3/9/2016Q415($0.08)($0.08)$1.51 million$1.76 millionViewN/AView Earnings Details
11/13/2015Q315($0.10)($0.11)$1.26 million$1.30 millionViewListenView Earnings Details
8/13/2015Q215($0.11)$0.05$0.92 million$0.96 millionViewListenView Earnings Details
5/11/2015Q115($0.13)($0.11)$0.80 million$0.72 millionViewListenView Earnings Details
8/12/2014Q2 2014($0.01)($0.01)$1.13 million$1.03 millionViewN/AView Earnings Details
3/31/2014Q4 2013($0.01)($0.01)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Cytosorbents Corp (NASDAQ:CTSO)
2017 EPS Consensus Estimate: ($0.34)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.11)($0.11)($0.11)
Q2 20172($0.07)($0.06)($0.07)
Q3 20172($0.08)($0.07)($0.08)
Q4 20172($0.09)($0.08)($0.09)
(Data provided by Zacks Investment Research)


Dividend History for Cytosorbents Corp (NASDAQ:CTSO)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Cytosorbents Corp (NASDAQ:CTSO)
Insider Ownership Percentage: 4.20%
Institutional Ownership Percentage: 6.07%
Insider Trades by Quarter for Cytosorbents Corp (NASDAQ:CTSO)
Institutional Ownership by Quarter for Cytosorbents Corp (NASDAQ:CTSO)
Insider Trades by Quarter for Cytosorbents Corp (NASDAQ:CTSO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/15/2017Kathleen P. BlochCFOBuy1,000$4.34$4,340.00View SEC Filing  
12/9/2016Phillip P. ChanInsiderBuy4,600$5.40$24,840.00View SEC Filing  
12/6/2016Kathleen P BlochCFOBuy1,000$4.83$4,830.00View SEC Filing  
8/24/2016Phillip P ChanInsiderBuy5,000$4.89$24,450.00View SEC Filing  
6/7/2016Michael G BatorDirectorBuy3,000$4.88$14,640.00View SEC Filing  
10/29/2015Vincent CapponiCOOSell4,000$7.50$30,000.00View SEC Filing  
10/15/2015Al KrausDirectorSell6,774$6.22$42,134.28View SEC Filing  
10/8/2015Al KrausDirectorSell10,000$6.39$63,900.00View SEC Filing  
10/1/2015Al KrausDirectorSell10,000$6.26$62,600.00View SEC Filing  
9/24/2015Al KrausDirectorSell10,000$6.44$64,400.00View SEC Filing  
9/17/2015Al KrausDirectorSell10,000$6.64$66,400.00View SEC Filing  
9/10/2015Al KrausDirectorSell10,000$7.26$72,600.00View SEC Filing  
9/3/2015Al KrausDirectorSell10,000$7.26$72,600.00View SEC Filing  
8/27/2015Al KrausDirectorSell10,000$6.39$63,900.00View SEC Filing  
8/20/2015Al KrausDirectorSell10,000$7.26$72,600.00View SEC Filing  
8/13/2015Al KrausDirectorSell10,000$6.26$62,600.00View SEC Filing  
7/23/2015Al KrausDirectorSell10,000$6.28$62,800.00View SEC Filing  
7/16/2015Al KrausDirectorSell10,000$6.33$63,300.00View SEC Filing  
7/9/2015Al KrausDirectorSell10,000$5.98$59,800.00View SEC Filing  
7/2/2015Al KrausDirectorSell10,000$6.29$62,900.00View SEC Filing  
6/25/2015Al KrausDirectorSell13,205$7.33$96,792.65View SEC Filing  
6/18/2015Al KrausDirectorSell10,000$5.78$57,800.00View SEC Filing  
6/11/2015Al KrausDirectorSell10,000$6.29$62,900.00View SEC Filing  
6/4/2015Al KrausDirectorSell10,000$6.30$63,000.00View SEC Filing  
5/28/2015Al KrausDirectorSell10,000$6.32$63,200.00View SEC Filing  
11/17/2014Al KrausDirectorSell50,000$0.23$11,500.00View SEC Filing  
11/10/2014Al KrausDirectorSell50,000$0.23$11,500.00View SEC Filing  
11/3/2014Al KrausDirectorSell50,000$0.23$11,500.00View SEC Filing  
10/27/2014Al KrausDirectorSell100,000$0.24$24,000.00View SEC Filing  
10/10/2014James T GuntonDirectorSell1,240,762$0.24$297,782.88View SEC Filing  
10/6/2014Al KrausDirectorSell50,000$0.23$11,500.00View SEC Filing  
9/29/2014Al KrausDirectorSell50,000$0.23$11,500.00View SEC Filing  
9/25/2014Al KrausDirectorSell41,500$0.23$9,545.00View SEC Filing  
9/22/2014Al KrausDirectorSell8,500$0.23$1,955.00View SEC Filing  
9/15/2014Al KrausDirectorSell50,000$0.23$11,500.00View SEC Filing  
9/12/2014James T GuntonDirectorSell30,450$0.24$7,308.00View SEC Filing  
9/8/2014Al KrausDirectorSell50,000$0.23$11,500.00View SEC Filing  
9/5/2014James T GuntonDirectorSell100,000$0.24$24,000.00View SEC Filing  
9/2/2014Al KrausDirectorSell50,000$0.25$12,500.00View SEC Filing  
9/2/2014Kathleen P BlochCFOBuy65,000$0.23$14,950.00View SEC Filing  
8/28/2014James T GuntonDirectorSell214,387$0.24$51,452.88View SEC Filing  
8/27/2014James T GuntonDirectorSell1,360,000$0.24$326,400.00View SEC Filing  
8/25/2014Al KrausDirectorSell100,000$0.25$25,000.00View SEC Filing  
8/18/2014Al KrausDirectorSell100,000$0.27$27,000.00View SEC Filing  
8/11/2014Al KrausDirectorSell100,000$0.28$28,000.00View SEC Filing  
8/4/2014Al KrausDirectorSell50,000$0.24$12,000.00View SEC Filing  
7/21/2014Al KrausDirectorSell50,000$0.24$12,000.00View SEC Filing  
7/10/2014Al KrausDirectorSell50,000$0.24$12,000.00View SEC Filing  
7/7/2014Al KrausDirectorSell50,000$0.24$12,000.00View SEC Filing  
6/23/2014Al KrausDirectorSell50,000$0.23$11,500.00View SEC Filing  
6/18/2014Al KrausDirectorSell50,000$0.24$12,000.00View SEC Filing  
5/20/2014Kathleen P BlochCFOBuy110,000$0.24$26,400.00View SEC Filing  
9/4/2012Phillip P ChanCEOBuy190,000$0.13$24,700.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Cytosorbents Corp (NASDAQ:CTSO)
Latest Headlines for Cytosorbents Corp (NASDAQ:CTSO)
DateHeadline logoCytoSorbents Selected to Present at Special Operations SOMSA 2017 Conference and 18th Annual B. Riley & Co. Investor Conference - May 24 at 12:40 PM logoCytosorbents Corp (CTSO) PT Set at $10.00 by Maxim Group - May 23 at 8:04 PM logoETFs with exposure to CytoSorbents Corp. : May 22, 2017 - May 22 at 4:22 PM logoAferetica and CytoSorbents Extend Exclusive "Life-saving" Partnership through 2021 - May 22 at 12:16 PM logoCytosorbents Corp (CTSO) to Post Q2 2017 Earnings of ($0.07) Per Share, Zacks Investment Research Forecasts - May 17 at 8:00 AM logoZacks: Analysts Expect Cytosorbents Corp (CTSO) Will Announce Earnings of -$0.08 Per Share - May 16 at 4:04 PM logoResearch Analysts Issue Forecasts for Cytosorbents Corp's FY2020 Earnings (CTSO) - May 16 at 1:48 PM logoCTSO: Revenue Acceleration Expected 2H. REFRESH Efficacy Compelling - May 16 at 12:11 PM logoCytosorbents Corp (CTSO) Earns "Buy" Rating from B. Riley - May 15 at 7:34 PM logoCytosorbents Corp to Post Q2 2017 Earnings of ($0.06) Per Share, B. Riley Forecasts (CTSO) - May 11 at 9:26 AM logoCytosorbents Corp (CTSO) Given "Buy" Rating at B. Riley - May 10 at 9:30 PM logoCytoSorbents Corp. :CTSO-US: Earnings Analysis: Q1, 2017 By the Numbers : May 10, 2017 - May 10 at 4:45 PM logoETFs with exposure to CytoSorbents Corp. : May 9, 2017 - May 9 at 9:33 PM logoCytosorbents Corp (CTSO) Posts Quarterly Earnings Results, Beats Expectations By $0.06 EPS - May 9 at 1:38 PM logoCytosorbents Corp (CTSO) Given "Buy" Rating at Aegis - May 9 at 10:26 AM logoCytoSorbents Reports First Quarter 2017 Financial Results - May 8 at 9:25 PM logoCytoSorbents reports 1Q loss - May 8 at 9:25 PM logoInvestor Network: CytoSorbents Corporation to Host Earnings Call - May 8 at 4:25 PM logoCytosorbents Corp's (CTSO) "Buy" Rating Reiterated at B. Riley - May 6 at 5:08 PM logoCytosorbents (CTSO) Presents REFRESH I Trial Results at AATS - - May 5 at 9:48 PM logoCytoSorbents Announces Positive REFRESH I Trial Results - May 5 at 4:47 PM logoCytoSorbents to Report Q1 2017 Operating and Financial Results - May 2 at 7:57 PM logoCytosorbents Corp (CTSO) Receives Media Sentiment Score of 0.44 - May 2 at 12:56 PM logoCytosorbents Corp (CTSO) Earns Coverage Optimism Score of 0.05 - April 29 at 2:51 PM logoZacks: Brokerages Anticipate Cytosorbents Corp (CTSO) Will Post Quarterly Sales of $2.99 Million - April 27 at 10:24 AM logoBiotech Forum Daily Digest: Biogen Kicks Off Earning Season In Style - Spotlight On Cytosorbents - April 27 at 1:58 AM logo-$0.11 Earnings Per Share Expected for Cytosorbents Corp (CTSO) This Quarter - April 26 at 12:03 AM logoCytosorbents Corp (CTSO) Receives News Sentiment Rating of 0.28 - April 25 at 7:26 PM logoCytosorbents Corp (CTSO) Rating Reiterated by Maxim Group - April 25 at 12:17 PM logoCytosorbents (CTSO) Granted $1M Phase II SBIR Contract by U.S. DOD to Advance Fungal Mycotoxin Blood Purification - April 24 at 4:27 PM logoCytoSorbents Awarded $1M Phase II SBIR Contract by U.S. Department of Defense to Advance Fungal Mycotoxin Blood Purification - April 24 at 9:15 AM logoCytosorbents Corp (CTSO) Getting Favorable Media Coverage, Study Finds - April 20 at 4:54 PM logoCytosorbents Corp (CTSO) Earns "Buy" Rating from Maxim Group - April 19 at 1:14 PM logoCytoSorbents 2017 - Propelling the Company to the "Next Level" - April 19 at 12:38 PM logoCTSO: Equity Raise, Cancer Applications, REFRESH I Data Upcoming - April 17 at 12:00 PM logoCytosorbents Corp (CTSO) Given News Impact Rating of 0.29 - April 13 at 12:08 PM logoB. Riley Equities Analysts Lift Earnings Estimates for Cytosorbents Corp (CTSO) - April 10 at 7:37 AM logoETFs with exposure to CytoSorbents Corp. : April 5, 2017 - April 7 at 9:16 AM logoCytosorbents Corp (CTSO) Earns Buy Rating from B. Riley - April 5 at 11:07 PM logoCYTOSORBENTS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits - April 3 at 10:00 PM logoWatch Out Below In Cytosorbents Corporation: A Reverse Merger Uplisting Running Low On Liquidity - April 1 at 8:53 AM logoCytosorbents (CTSO) Prices 2.22M Share Follow-On Offering at $4.50 - March 31 at 4:42 PM logoCytoSorbents Announces Pricing of Follow-On Offering - March 31 at 4:42 PM logoCytoSorbents Announces Proposed Offering of Common Stock - March 30 at 5:00 PM logoCytoSorbents Strengthens Intellectual Property Portfolio with New Patents Issued in the U.S., China, Japan, Russia, and Australia - March 28 at 12:24 PM logoCytosorbents Corp (CTSO) Stock Rating Reaffirmed by Maxim Group - March 28 at 9:08 AM logoCytosorbents (CTSO) Announces REFRESH I Trial Abstract ... - - March 27 at 4:25 PM logoCytoSorbents REFRESH I Trial Abstract Selected for Podium Presentation at the American Association for Thoracic Surgery Centennial Conference - March 27 at 12:23 PM logoDr. Carl H. June, Cancer Immunotherapy Pioneer, Joins CytoSorbents Scientific Advisory Board - March 22 at 4:41 PM logoCytosorbents Corp (CTSO) Earns Buy Rating from Maxim Group - March 22 at 8:13 AM



Cytosorbents Corp (CTSO) Chart for Thursday, May, 25, 2017

This page was last updated on 5/25/2017 by Staff